Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-881 in Healthy Adults

NCT05059977
Conditions
Healthy Volunteers
Interventions
TAK-881
Biological
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hialeah, Florida
Conditions
Primary Immunodeficiency
Interventions
IGSC 20%
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
6 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • North Palm Beach, Florida + 8 more
Conditions
CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Interventions
Gamunex-C, Xembify
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 6 more
Conditions
Primary Immunodeficiency
Interventions
IGIV-C 10%, IGSC 20%
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
2 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
20
States / cities
Los Angeles, California • Santa Monica, California • Denver, Colorado + 17 more
Conditions
Primary Immunodeficiency
Interventions
IGSC 20% daily push versus every 2 weeks pump, IGSC 20% daily push versus once a week pump, IGSC 20% daily push versus 2 times per week pump, IGSC 20% 150 mg/kg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
2 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
South Bend, Indiana • Columbus, Ohio • Oklahoma City, Oklahoma + 1 more
Completed Phase 2Phase 3 Interventional Results available

Phase 2/3 Study of IGSC, 20% in PIDD

NCT01218438
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Intravenous (Human), 10% Solution, Immune Globulin Subcutaneous (Human), 20% Solution
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Irvine, California • Centennial, Colorado • North Palm Beach, Florida + 13 more
Conditions
Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Interventions
Xembify, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more